Flag of the European Union EU Clinical Trials Register Help

Clinical trials for placebo

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    12,689 result(s) found for: placebo. Displaying page 235 of 635.
    «« First « Previous 231  232  233  234  235  236  237  238  239  Next» Last»»
    EudraCT Number: 2007-003159-36 Sponsor Protocol Number: EFC10290 Start Date*: 2007-10-24
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patient...
    Medical condition: Treatment of Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000678-57 Sponsor Protocol Number: S308.3.003 Start Date*: 2007-06-18
    Sponsor Name:Solvay pharmaceuticals
    Full Title: A multicenter, randomized, double blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of SLV308 monotherapy in the treatment of patients with early stage Pa...
    Medical condition: Parkinson 's Disease early stage
    Disease: Version SOC Term Classification Code Term Level
    8.1 10013113 Disease Parkinson's LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PT (Completed) EE (Completed) LT (Completed) DE (Completed) FR (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-002310-31 Sponsor Protocol Number: INCB24360-303 Start Date*: 2018-04-13
    Sponsor Name:Incyte Corporation
    Full Title: Phase 3 Randomized, Double-Blind Clinical Study of Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo as a Treatment for Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who...
    Medical condition: Recurrent or Progressive Metastatic Urothelial Carcinoma in Patients who have Failed a First-Line Platinum-containing Chemotherapy Regimen for Advanced/Metastatic Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Temporarily Halted) HU (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003200-48 Sponsor Protocol Number: EP0091 Start Date*: 2018-04-09
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug- Res...
    Medical condition: Focal-Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) HU (Completed) CZ (Completed) BE (Completed) ES (Completed) FR (Completed) BG (Completed) LT (Completed) SK (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004068-13 Sponsor Protocol Number: HALO-109-301 Start Date*: 2016-03-02
    Sponsor Name:Halozyme, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With nab-Paclitaxel Plus Gemcitabine Compared With P...
    Medical condition: Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) HU (Completed) BE (Completed) GB (Prematurely Ended) LT (Prematurely Ended) DE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) FR (Completed) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005321-40 Sponsor Protocol Number: CUV015 Start Date*: 2007-01-19
    Sponsor Name:Clinuvel Pharmaceuticals Limited
    Full Title: A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of CUV1647 in patients suffering from polymorphic light eruption (PLE).
    Medical condition: Polymorphic light eruption (PLE)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036087 Polymorphic light eruption PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FI (Completed) AT (Completed) BE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000218-20 Sponsor Protocol Number: LICC01 Start Date*: 2011-09-21
    Sponsor Name:Universitätsmedizin Mainz
    Full Title: LICC: L-BLP25 in Patients with Colorectal Carcinoma after curative resection of hepatic metastases – a randomized, placebo-controlled, multicenter, multinational, double blinded phase II trial
    Medical condition: Patients with metastatic colorectal carcinoma (CRC), who have undergone a complete resection of their primary tumor and recent resection of their liver metastases (R0 or R1) with curative intent.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001841-40 Sponsor Protocol Number: GW685698X Start Date*: 2005-10-05
    Sponsor Name:GlaxoSmithKline Research And Development Ltd
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 200mcg Twice-Daily, GW685698X Inhalation Powder ...
    Medical condition: Persistent asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LV (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020426-18 Sponsor Protocol Number: IMCLCP12-0922 Start Date*: 2010-10-27
    Sponsor Name:ImClone LLC
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinom...
    Medical condition: Metastatic gastric or gastroesophageal adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10063916 Metastatic gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) HU (Completed) RO (Completed) FR (Completed) GB (Completed) AT (Completed) LT (Completed) PT (Completed) EE (Completed) IT (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019925-33 Sponsor Protocol Number: D4130C00003 Start Date*: Information not available in EudraCT
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III Efficacy and Safety Study of TC-5214 (S-mecamylamine) in Flexible Doses as an Adjunct to an Antidepressant in ...
    Medical condition: Adjunct treatment to an antidepressant in patients with Major Depressive Disorder who exhibit an inadequate response to antidepressant therapy
    Disease: Version SOC Term Classification Code Term Level
    13.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    13.1 10037175 - Psychiatric disorders 10025453 Major depressive disorder NOS LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) SE (Completed) LT (Completed) EE (Completed) LV (Completed) CZ (Completed) FR (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2018-000464-29 Sponsor Protocol Number: CAT-1004-301 Start Date*: 2019-01-31
    Sponsor Name:Catabasis Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, GLOBAL PHASE 3 STUDY OF EDASALONEXENT IN PEDIATRIC PATIENTS WITH DUCHENNE MUSCULAR DYSTROPHY
    Medical condition: Duchenne muscular dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10013801 Duchenne muscular dystrophy PT
    Population Age: Children, Under 18 Gender: Male
    Trial protocol: DE (Completed) SE (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005625-39 Sponsor Protocol Number: I8D-MC-AZET Start Date*: 2016-09-16
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer’s Disease Dementia (The DAYBREAK Study)
    Medical condition: Alzheimer’s Disease with Dementia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) PL (Prematurely Ended) CZ (Prematurely Ended) DK (Completed) NL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001409-40 Sponsor Protocol Number: S334.2.002 Start Date*: 2009-03-04
    Sponsor Name:Solvay Pharmaceuticals B.V.
    Full Title: A Randomized, Double blind, Placebo-Controlled Dose Escalation Study to Investigate the Safety and Pharmacokinetics after Single and Multiple Doses of SLV334 in Sequential Cohorts of Patients with ...
    Medical condition: Moderate and severe Traumatic Brain Injury (TBI)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060690 Traumatic brain injury PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000392-28 Sponsor Protocol Number: 1199.214 Start Date*: 2015-11-02
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with Systemic Sclerosis associated Interstitial Lu...
    Medical condition: Patients with Systemic Sclerosis and associated Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10012977 Diffuse systemic sclerosis LLT
    19.1 100000004859 10036814 Progressive systemic sclerosis LLT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10042954 Systemic sclerosis pulmonary PT
    19.1 10038738 - Respiratory, thoracic and mediastinal disorders 10025109 Lung involvement in systemic sclerosis LLT
    19.1 100000004859 10042953 Systemic sclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed) PT (Completed) DK (Completed) BE (Completed) ES (Completed) GR (Completed) FR (Completed) PL (Completed) IE (Completed) FI (Completed) NO (Completed) SE (Completed) AT (Completed) HU (Prematurely Ended) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000244-24 Sponsor Protocol Number: A3871027 Start Date*: 2004-08-18
    Sponsor Name:Pfizer AB
    Full Title: A Phase 2b, multi-center, double-blind, placebo-controlled, parallel group dose response study to assess the efficacy and safety of oral UK-390,957 in men with premature ejaculation.
    Medical condition: Premature Ejaculation
    Disease: Version SOC Term Classification Code Term Level
    7.0 10036596 LLT
    Population Age: Adults Gender: Male
    Trial protocol: SE (Completed) HU (Completed) IT (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-004167-37 Sponsor Protocol Number: ZX008-1502 Start Date*: 2016-05-17
    Sponsor Name:Zogenix International Limited
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and You...
    Medical condition: Dravet's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) NO (Ongoing) DK (Completed) SE (Ongoing) ES (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022923-31 Sponsor Protocol Number: FIinTIC Start Date*: Information not available in EudraCT
    Sponsor Name:Medizinische Universität Innsbruck / Univ.-Klinik für Allgem. u. Chirurg. Intensivmedizin
    Full Title: A multicenter double-blind, placebo controlled, randomized, pilot trial to assess the efficacy of pre-hospital administration of Fibrinogen Concentrate (FGTW) in trauma patients, presumed to bleed ...
    Medical condition: Trauma patients with major bleeding or occult bleeding who received volume replacement
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10018988 Haemorrhage NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2005-003777-24 Sponsor Protocol Number: PKU-006 Start Date*: 2006-03-24
    Sponsor Name:BioMarin Pharmaceutical Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Phenoptin 20 mg/kg/day to Increase Phenylalanine Tolerance in Phenylketonuric Child...
    Medical condition: Phenylketonuria (PKU)
    Disease: Version SOC Term Classification Code Term Level
    6.1 10034872
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001567-55 Sponsor Protocol Number: DAC-1012 Start Date*: 2006-06-23
    Sponsor Name:Protein Design Labs, Inc.
    Full Title: A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis
    Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002708-28 Sponsor Protocol Number: REDIV/002/17 Start Date*: 2018-02-23
    Sponsor Name:Alfasigma S.p.a
    Full Title: Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized ...
    Medical condition: Prevention of recurrent acute diverticulitis and diverticular complications
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052812 Acute diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 231  232  233  234  235  236  237  238  239  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 04 14:37:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA